Not one, but many: developing a multi-indication pricing model for medicines in Belgium
Back ground: Current pricing and reimbursement models that focus on one indication at a time are not suited to address the market access of multi-indication medicines. Therefore, the aim of this study is to co-create with Belgian stakeholders a multi-indication pricing model and procedural pathway, to identify conditions for implementation, and to illustrate the multi-indication pricing model with a case study. Methods: Different multi-indication pricing models were identified from the literature, case studies and pilots in other countries. Semi-structured interviews were conducted with 21 rep... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Frontiers in Pharmacology ; volume 14 ; ISSN 1663-9812 |
Verlag/Hrsg.: |
Frontiers Media SA
|
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-27393682 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.3389/fphar.2023.1199253 |